Statement on the planned hepatitis B birth dose vaccine trial in Guinea-Bissau at AshTip Solution.

AshTip NewsLetter |The World Health Organization (WHO) underscores that the hepatitis B birth dose vaccine is an effective, and essential public health intervention, with a proven record. It prevents life‑threatening liver disease by stopping mother‑to‑child transmission at birth.

WHO Org

Statement on the planned hepatitis B birth dose vaccine trial in Guinea-Bissau

Statement on the planned hepatitis B birth dose vaccine trial in Guinea-Bissau

The World Health Organization (WHO) underscores that the hepatitis B birth dose vaccine is an effective, and essential public health intervention, with a proven record. It prevents life‑threatening liver disease by stopping mother‑to‑child transmission at birth. It has been used for over three decades, with more than 115 countries including it in their national schedules. Protecting newborns with a timely birth dose not only provides individual benefit but is also central to national and global elimination efforts.